Welcome to our dedicated page for Ovid Therapeutics SEC filings (Ticker: OVID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hundreds of pages on trial endpoints, cash-runway tables, and licensing clauses can make Ovid Therapeutics Inc’s disclosures feel impenetrable. If you have ever typed “Ovid Therapeutics SEC filings explained simply” or wondered how a failed Phase-2 update appears in an 8-K, you know the challenge of parsing biotech jargon.
Stock Titan’s AI-powered analysis converts every Ovid Therapeutics quarterly earnings report 10-Q filing and annual report 10-K simplified into concise, decision-ready summaries. Our engine streams Ovid Therapeutics Form 4 insider transactions real-time, highlights option grants, and links each material event so you don’t have to wade through EDGAR. Need the Ovid Therapeutics proxy statement executive compensation details or to verify Ovid Therapeutics executive stock transactions Form 4? They’re surfaced instantly, alongside plain-English context.
- Track Ovid Therapeutics insider trading Form 4 transactions minutes after they post.
- Run AI-driven Ovid Therapeutics earnings report filing analysis to compare R&D spend and cash runway quarter over quarter.
- Receive alerts when an Ovid Therapeutics 8-K material events explained summary flags new clinical data or partnership news.
Whether you are understanding Ovid Therapeutics SEC documents with AI ahead of a financing round or scanning past S-3 and S-8 issuances, Stock Titan delivers complete, real-time coverage of every filing type—10-K, 10-Q, 8-K, Form 4, and more—paired with expert insight so you can make informed decisions faster.
Ovid Therapeutics (NASDAQ:OVID) has amended its Exclusive Patent License Agreement with Immedica Pharma AB through Amendment No. 1, effective June 23, 2025. The key modification involves Immedica purchasing ongoing royalty obligations for $7.0 million in cash, payable within 10 business days. The original agreement granted Marinus (now an Immedica subsidiary) exclusive rights to ganaxolone for CDKL5 deficiency disorder treatment in the US and Europe. The amendment also provides Immedica with additional patent prosecution rights and anticipates a second amendment within six months to expand territory coverage and rights to other necessary patents.
Form 4 overview: Director Kevin J. Fitzgerald of Ovid Therapeutics Inc. (NASDAQ: OVID) reported the grant of a stock option for 45,000 shares on 02/20/2025 at an exercise price of $0.57 per share.
The option is classified as an acquisition (Code “A”) of derivative securities. It will vest 100 % on 02/20/2026, provided the director remains in continuous service, and will expire on 02/19/2035. Following the transaction, Fitzgerald beneficially owns 45,000 derivative securities, all held directly.
No common-stock transactions, sales, or additional derivative dispositions were reported. Because this filing reflects a routine director equity grant rather than an open-market purchase or sale, it typically has limited immediate trading impact but does strengthen long-term alignment between the director and shareholders.
Form 4 Filing Details: Bart Friedman, Director of Ovid Therapeutics (OVID), received a stock option grant for 45,000 shares of common stock on February 20, 2025. The filing was reported on June 28, 2025.
Key Transaction Terms:
- Option exercise price set at $0.57 per share
- Options will vest fully on February 20, 2026, contingent on continuous service
- Options expire on February 19, 2035
- Transaction reported as a Direct (D) ownership
This grant appears to be part of the company's director compensation program. The significant discount in the exercise price compared to typical market prices could indicate either a period of stock price decline or a deliberate incentive structure to align director interests with shareholders.
Insider Trading Alert: Barbara Gayle Duncan, Director at Ovid Therapeutics (OVID), received a stock option grant on February 20, 2025. The transaction details include:
- Granted 45,000 stock options to purchase common stock
- Exercise price set at $0.57 per share
- Options will vest fully on February 20, 2026, contingent on continuous service
- Options expire on February 19, 2035
This Form 4 filing, reported by the director's attorney-in-fact Jason Minio on June 18, 2025, represents a standard equity compensation grant for board service. The relatively low exercise price and one-year cliff vesting schedule suggest this is part of the company's regular director compensation program.
Ovid Therapeutics director Karen Bernstein received a stock option grant for 45,000 shares of common stock on February 20, 2025. The key details of this Form 4 filing include:
- Option exercise price set at $0.57 per share
- Options will vest fully on February 20, 2026, contingent on continuous service
- Expiration date is set for February 19, 2035
- The derivative securities are held directly by the reporting person
This grant represents a standard director compensation package and aligns the director's interests with shareholders through long-term equity incentives. The one-year cliff vesting schedule encourages retention while the ten-year exercise window provides flexibility in execution timing.
FAQ
What is the current stock price of Ovid Therapeutics (OVID)?
What is the market cap of Ovid Therapeutics (OVID)?
What is the primary focus of Ovid Therapeutics Inc?
How does Ovid Therapeutics generate revenue?
What distinguishes Ovid Therapeutics’ drug pipeline?
What therapeutic areas does Ovid’s research cover?
How does Ovid Therapeutics approach clinical research?
What type of collaborations does Ovid Therapeutics engage in?
In what ways does Ovid Therapeutics differentiate itself from competitors?
How does Ovid Therapeutics ensure scientific rigor in its programs?
